Discounted Cash Flow
Nanobiotix S.A. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $116.0k | $-30.3m | $-26.4m | -26159.5% | $-1.55 |
| 2019 | $2.5m (2090.5%) | $-50.9m (-67.8%) | $-42.3m (-60.1%) | -2003.7% (92.3%) | $-2.35 (-51.6%) |
| 2020 | $2.5m (-1.1%) | $-33.6m (34.0%) | $-27.6m (34.6%) | -1337.2% (33.3%) | $-1.38 (41.3%) |
| 2021 | $5.3m (110.4%) | $-47.1m (-40.1%) | $-30.1m (-8.9%) | -890.7% (33.4%) | $-1.35 (2.2%) |
| 2022 | $9.6m (80.8%) | $-57.0m (-21.2%) | $-37.2m (-23.6%) | -597.2% (33.0%) | $-1.64 (-21.5%) |
| 2023 | $30.1m (214.7%) | $-39.7m (30.4%) | $-12.8m (65.6%) | -132.1% (77.9%) | $-1.08 (34.1%) |
| 2024 | $-2.6m (-108.7%) | $-68.1m (-71.6%) | $-20.4m (-59.3%) | 2595.5% (2065.1%) | $-1.44 (-33.3%) |
| 2025 | $29.6m (1229.3%) | $-24.0m (64.8%) | $-34.0m (-66.5%) | -80.8% (-103.1%) | $-0.50 (65.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.